Your browser doesn't support javascript.
loading
Prophylactic use of carvedilol to prevent ventricular dysfunction in patients with cancer treated with doxorubicin.
Abuosa, Ahmed Mohamed; Elshiekh, Ayman Hassan; Qureshi, Kahekashan; Abrar, Mohammed Burhan; Kholeif, Mona A; Kinsara, Abdulhalim Jamal; Andejani, Abdulwahab; Ahmed, Adel H; Cleland, John G F.
Afiliación
  • Abuosa AM; King Saud bin Abdulaziz University for Health Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Saudi Arabia.
  • Elshiekh AH; King Saud bin Abdulaziz University for Health Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Saudi Arabia.
  • Qureshi K; Princess Noorah Oncology Centre, Jeddah, Saudi Arabia.
  • Abrar MB; Princess Noorah Oncology Centre, Jeddah, Saudi Arabia.
  • Kholeif MA; King Saud bin Abdulaziz University for Health Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Saudi Arabia.
  • Kinsara AJ; King Saud bin Abdulaziz University for Health Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Saudi Arabia. Electronic address: kinsaraaj@ngha.med.sa.
  • Andejani A; Princess Noorah Oncology Centre, Jeddah, Saudi Arabia.
  • Ahmed AH; King Saud bin Abdulaziz University for Health Sciences, COM-J, King Abdul Aziz Medical City-WR, King Faisal Cardiac Center, Saudi Arabia.
  • Cleland JGF; National Heart & Lung Institute, Royal Brompton & Harefield Hospitals, Imperial College, London, United Kingdom.
Indian Heart J ; 70 Suppl 3: S96-S100, 2018 Dec.
Article en En | MEDLINE | ID: mdl-30595329
OBJECTIVE: Deterioration in ventricular function is often observed in patients treated with anthracyclines for cancer. There is a paucity of evidence on interventions that might provide cardio-protection. We investigated whether prophylactic use of carvedilol can prevent doxorubicin-induced cardiotoxicity and whether any observed effect is dose related. METHODS: A prospective, randomized, double-blind study in patients treated with doxorubicin, comparing placebo (n = 38) with different doses of carvedilol [6.25 mg/day (n = 41), 12.5 mg/day (n = 38) or 25 mg/day (n = 37)]. The primary endpoint was the measured change in left ventricular ejection fraction (LVEF) from baseline to 6 months. RESULTS: LVEF decreased from 62 ±â€¯5% at baseline to 58 ±â€¯7% at 6-months (p = 0.002) in patients assigned to placebo but no statistically significant changes were observed in any of the 3 carvedilol groups. At 6 months, only one of 116 patients (1%) assigned to carvedilol had an LVEF < 50% compared to four of the 38 assigned to placebo (11%), (p = 0.013). No significant differences were noted between carvedilol and placebo in terms of the development of diastolic dysfunction, clinically overt heart failure or death. CONCLUSIONS: Carvedilol might prevent deterioration in LVEF in cancer patients treated with doxorubicin. This effect may not be dose related within the studied range.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Volumen Sistólico / Doxorrubicina / Disfunción Ventricular Izquierda / Carvedilol / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Indian Heart J Año: 2018 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: India
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Volumen Sistólico / Doxorrubicina / Disfunción Ventricular Izquierda / Carvedilol / Neoplasias Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies Límite: Adult / Female / Humans / Male / Middle aged Idioma: En Revista: Indian Heart J Año: 2018 Tipo del documento: Article País de afiliación: Arabia Saudita Pais de publicación: India